Literature DB >> 22533566

Metabolomic investigations of human infections.

Tiziana Pacchiarotta1, André M Deelder, Oleg A Mayboroda.   

Abstract

Metabolomics has a special place among other 'omics' disciplines (genomics, transcriptomics and proteomics) as it describes the most dynamic level of biological regulation and, as such, provides the most direct reflection of the physiological status of an organism. Quick development of the analytical technologies in the first place - MS and NMR - has enabled the metabolomics analysis of such complex biological phenomena as host-pathogen interactions in the development of infection. In this review, an overview of the metabolomics studies of infectious diseases carried out on human material is provided. The relevant papers on the metabolomics of human infectious diseases are comprehensively summarized in a table, including, for example, information on the study design, number of subjects, employed technology and metabolic discriminator. Future considerations, such as importance of the time-resolved study designs and the embedment of metabolomics in large-scale epidemiological studies are discussed.

Entities:  

Mesh:

Year:  2012        PMID: 22533566     DOI: 10.4155/bio.12.61

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  10 in total

Review 1.  Metabolomics: Applications and Promise in Mycobacterial Disease.

Authors:  Mehdi Mirsaeidi; Mohammad Mehdi Banoei; Brent W Winston; Dean E Schraufnagel
Journal:  Ann Am Thorac Soc       Date:  2015-09

Review 2.  A review of metabolomics approaches and their application in identifying causal pathways of childhood asthma.

Authors:  Kedir N Turi; Lindsey Romick-Rosendale; Kelli K Ryckman; Tina V Hartert
Journal:  J Allergy Clin Immunol       Date:  2017-05-04       Impact factor: 10.793

3.  Application of (1)h NMR spectroscopy-based metabolomics to sera of tuberculosis patients.

Authors:  Aiping Zhou; Jinjing Ni; Zhihong Xu; Ying Wang; Shuihua Lu; Wei Sha; Petros C Karakousis; Yu-Feng Yao
Journal:  J Proteome Res       Date:  2013-09-10       Impact factor: 4.466

Review 4.  Metabolomics in chronic pain research.

Authors:  Shweta Teckchandani; G A Nagana Gowda; Daniel Raftery; Michele Curatolo
Journal:  Eur J Pain       Date:  2020-11-05       Impact factor: 3.931

5.  Metabolomics-Based Discovery of Small Molecule Biomarkers in Serum Associated with Dengue Virus Infections and Disease Outcomes.

Authors:  Natalia V Voge; Rushika Perera; Sebabrata Mahapatra; Lionel Gresh; Angel Balmaseda; María A Loroño-Pino; Amber S Hopf-Jannasch; John T Belisle; Eva Harris; Carol D Blair; Barry J Beaty
Journal:  PLoS Negl Trop Dis       Date:  2016-02-25

Review 6.  Guide to Metabolomics Analysis: A Bioinformatics Workflow.

Authors:  Yang Chen; En-Min Li; Li-Yan Xu
Journal:  Metabolites       Date:  2022-04-15

7.  Cell scale host-pathogen modeling: another branch in the evolution of constraint-based methods.

Authors:  Neema Jamshidi; Anu Raghunathan
Journal:  Front Microbiol       Date:  2015-10-06       Impact factor: 5.640

8.  Metabolic characterization of the natural progression of chronic hepatitis B.

Authors:  Johannes C Schoeman; Jun Hou; Amy C Harms; Rob J Vreeken; Ruud Berger; Thomas Hankemeier; Andre Boonstra
Journal:  Genome Med       Date:  2016-06-10       Impact factor: 11.117

9.  Integrative omics to detect bacteremia in patients with febrile neutropenia.

Authors:  Rachel S Kelly; Jessica Lasky-Su; Sai-Ching J Yeung; Richard M Stone; Jeffrey M Caterino; Sean C Hagan; Gary H Lyman; Lindsey R Baden; Brett E Glotzbecker; Christopher J Coyne; Christopher W Baugh; Daniel J Pallin
Journal:  PLoS One       Date:  2018-05-16       Impact factor: 3.240

10.  Type III Secretion Effector VopQ of Vibrio parahaemolyticus Modulates Central Carbon Metabolism in Epithelial Cells.

Authors:  Anh Quoc Nguyen; Takaaki Shimohata; Sho Hatayama; Aya Tentaku; Junko Kido; Thi Mai Huong Bui; Takashi Uebanso; Kazuaki Mawatari; Akira Takahashi
Journal:  mSphere       Date:  2020-03-18       Impact factor: 4.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.